Skip Navigation
Search Menu
Find an Expert

 


Matthias Holdhoff, M.D., Ph.D.

Photo of Dr. Matthias Holdhoff, M.D., Ph.D.

Assistant Professor of Oncology

Male

Languages: English, French, German

Expertise: Brain Cancer, Brain Tumors, Medical Oncology , Neuro-Oncology, Primary central nervous system (CNS) lymphoma

Research Interests: Clinical Trials in Primary Brain Cancers; Translational Research in Neuro-Oncology

Request an Appointment

I live in Maryland

410-955-8964
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8964

Sibley Memorial Hospital

5255 Loughboro Road NW
Washington, DC 20016 map
Phone: 202-660-6500

Background

Dr. Matthias Holdhoff is a medical oncologist in the Brain Cancer Program at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, as well as assistant professor of oncology and neurological surgery at Johns Hopkins University School of Medicine.  Dr. Holdhoff’s expertise is on primary brain cancers and central nervous system lymphomas.  He practices out of the Sidney Kimmel Comprehensive at Johns Hopkins Hospital in Baltimore and he has a clinic at Sibley Memorial Hospital in Washington, DC.  He is board certified in internal medicine and medical oncology.  

Dr. Holdhoff earned his medical degree from Freie Universität Berlin and received his doctorate degree at Charité University Medicine Berlin. He completed a residency in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training within the Ludwig Center for Cancer Genetics and Therapeutics (Vogelstein lab).

Dr. Holdhoff is a clinical translational investigator in neuro-oncology.  His research is focused on novel trials in malignant gliomas, including glioblastomas, and on translational biomarker research in brain cancers.  He has led and contributed to numerous clinical trials, publications and presentations.  

Dr. Holdhoff is panel member for the National Comprehensive Cancer Network’s guidelines for cancers of the central nervous system. He was recipient of a 2010 ASCO Young Investigator Award and Merit Award and he was awarded the Director’s Teaching Award in Clinical Sciences at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.  He is faculty on the Janeway firm of the Osler Internal Medicine Residency Program at Johns Hopkins Hospital.

...read more

Titles

  • Assistant Professor of Oncology
  • Assistant Professor of Neurosurgery
  • Joint Appointment in Medicine

Departments / Divisions

Education

Degrees

  • MD, Freie Universitat Berlin (2003)

Residencies

  • Johns Hopkins Bayview Medical Center / Internal Medicine (2007)

Fellowships

  • Johns Hopkins University School of Medicine / Oncology (2010)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2007, 2017)
  • American Board of Internal Medicine / Oncology (2009, 2019)

Research & Publications

Research Summary

Dr. Holdhoff's research is focused on translational research projects and clinical trials in neuro-oncology.  His clinical research is concentrated on early phase therapeutic clinical trials in malignant gliomas, including glioblastomas.  He is leading or participating in multiple brain cancer trials, including within the Adult Brain Tumor Consortium.  In addition, he is working on novel biomarkers to assess response and disease activity in malignant gliomas.

Selected Publications

Dr. Holdhoff's research is focused on translational research projects and clinical trials in neuro-oncology. As a member of the Brain Cancer Program and the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins, he heads a working group for the development of blood-based biomarkers in malignant gliomas. Dr. Holdhoff graduated from medical school at Freie Universitt Berlin and he received his doctorate degree (German PhD equivalent) at Charit University Medicine Berlin. After internal medicine training at Johns Hopkins Bayview Medical Center he completed his medical oncology fellowship and subspecialty training in neuro-oncology at the Sidney Kimmel Comprehensive Cancer Center. Dr. Holdhoff is board certified in internal medicine and medical oncology and he has a clinic for patients with primary brain tumors, CNS lymphomas and other malignancies of the central nervous system.

Journal Citations
Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, Cao B, Olivi A, Grossman SA. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J. Neurooncol 2010; 97: 241-5 (Epub ahead of print Sept 19, 2009).
Holdhoff M, Schmidt K, Donehower R, Diaz LA, Jr. Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations. J Natl Cancer Inst 2009; 101: 1284-5.
Holdhoff M, Parsons DW, Diaz LA, Jr. Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. J Neurooncol 2009; 94: 297 (Epub ahead of print April 7).
Holdhoff M, Wung PK, Petronis JD, Couzi R. Persistent positron emission tomography-positive liver lesions after successful chemotherapy in mediastinal seminoma. J Clin Oncol. 2007; 25: 2482-4.
Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Drken B, le Coutre P. Radiosensitization of a human glioblastoma cell line by imatinib mesylate through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005; 34: 181-185.
le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA: Imatinib in Philadelphia chromosome positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome. Am J Hematol 2003; 73: 249-255.
le Coutre P, Kreuzer KA, Na IK, Lupberger J, Holdhoff M, Appelt, C, Schwarz M, Mller C, Gambacorti-Passerini C, Platzbecker U, Bonnet R, Ehninger G, Schmidt CA: Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukaemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002; 28: 75-85.
Is this you? Edit Profile